We are raising up to $60mm of funding at a $300mm pre-money valuation in a Series B Preferred Stock.  The goal for the company to have an IPO in late 2026.  The family has invested over $200mm into this company and will be investing in the Series B.  We have commitments of over $10mm from outside investors already.

Overview

AgNovos Bioscience is a regenerative medicine company focused on improving patient outcomes by restoring the native structure and biomechanics of bone. The Company's initial focus is to utilize its resorbable biomaterial platform to transform the treatment paradigm for patients with osteoporosis, a disease with well-defined and persistent unmet medical needs.

Osteoporosis impacts over 200 million women and men globally and is the leading cause of over 12 million fragility fractures annually. Notably, hip and spine fractures cause significant morbidity and mortality, with over 25% of hip fracture patients dying in the 12 months following the fracture and 40% of patients having increased disability and reduced quality of life. As much as a third of those with increased disability are no longer able to walk independently following fracture. A fact that astonished me to learn is that a woman's risk of breaking her hip is equal to her combined risk of breast, uterine and ovarian cancer. Current systemic treatments leave significant unmet needs both in efficacy and compliance.

Our Solution

AgNovos’ lead product, the Local Osteo-Enhancement Procedure ("LOEP") kit, is the first-ever targeted approach to treat diseased osteoporotic bone. Through a minimally invasive procedure, the surgeon delivers a targeted treatment that provides immediate strength to the bone and is then gradually resorbed and replaced by bone. The resultant increase in bone strength can reduce a patient's risk of fracture and maintain their mobility and quality of life.

A second product targets vertebral compression fractures in the spine. Both products have started what is called their “pivotal” trials. The spine product has received "breakthrough" designation from the FDA and is the only such product that has been fast-track designated for the spine that I know of so far. We got this fast track because there are 5 or 6 specific shortcomings in the current standard of care products which our product does not have. So FDA’s understanding of our product and that it might be a solution could mean they would like to see it pass through pivotal trials sooner.

With the fast-track designation, we were able to accomplish in 2 1/2 years what it took us 6 years to do for the hip. Indeed, the FDA has recognized that our material does in-fact, create bone which we feel is a validation of our material and procedure and our ability to work with the FDA.

We are raising up to $60mm of funding at a $300mm pre-money valuation in a Series B Preferred Stock.  The goal for the company to have an IPO in late 2026.  The family has invested over $200mm into this company and will be investing in the Series B.  We have commitments of over $10mm from outside investors already.

Overview

AgNovos Bioscience is a regenerative medicine company focused on improving patient outcomes by restoring the native structure and biomechanics of bone. The Company's initial focus is to utilize its resorbable biomaterial platform to transform the treatment paradigm for patients with osteoporosis, a disease with well-defined and persistent unmet medical needs.

Osteoporosis impacts over 200 million women and men globally and is the leading cause of over 12 million fragility fractures annually. Notably, hip and spine fractures cause significant morbidity and mortality, with over 25% of hip fracture patients dying in the 12 months following the fracture and 40% of patients having increased disability and reduced quality of life. As much as a third of those with increased disability are no longer able to walk independently following fracture. A fact that astonished me to learn is that a woman's risk of breaking her hip is equal to her combined risk of breast, uterine and ovarian cancer. Current systemic treatments leave significant unmet needs both in efficacy and compliance.

Our Solution

AgNovos’ lead product, the Local Osteo-Enhancement Procedure ("LOEP") kit, is the first-ever targeted approach to treat diseased osteoporotic bone. Through a minimally invasive procedure, the surgeon delivers a targeted treatment that provides immediate strength to the bone and is then gradually resorbed and replaced by bone. The resultant increase in bone strength can reduce a patient's risk of fracture and maintain their mobility and quality of life.

A second product targets vertebral compression fractures in the spine. Both products have started what is called their “pivotal” trials. The spine product has received "breakthrough" designation from the FDA and is the only such product that has been fast-track designated for the spine that I know of so far. We got this fast track because there are 5 or 6 specific shortcomings in the current standard of care products which our product does not have. So FDA’s understanding of our product and that it might be a solution could mean they would like to see it pass through pivotal trials sooner.

With the fast-track designation, we were able to accomplish in 2 1/2 years what it took us 6 years to do for the hip. Indeed, the FDA has recognized that our material does in-fact, create bone which we feel is a validation of our material and procedure and our ability to work with the FDA.